Jefferies Initiates Hold Rating on Merck (MRK)

Jefferies & Company is out with a brief analyst note this morning, where it initiates a Hold rating on Merck & Co. MRK; it has a $39.00 price target on the stock. The Jefferies analysts said that Merck faces several major binary risks over the next few years, most of which carry notable downside risk. They added that, with the unpredictable and near-term nature of the Remicade/Simponi arbitration, they are initiating coverage with a Hold rating, whilst they can clearly see room for better than expected mid-term EPS growth. Merck & Co., Inc. is a global health care company that delivers health solutions through its medicines, vaccines, biologic therapies, and consumer and animal products, which it markets directly and through its joint ventures. The company's operations are principally managed on a products basis. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, sold by prescription, for the treatment of human disorders. You Can't Afford Miss To Out On These Money Making Trading Ideas.